Diabetes Drug Slows Aging – Potential Breakthrough
- The henagliflozin study is a fascinating growth,highlighting the growing intersection of diabetes research and longevity science.
- Henagliflozin, approved for type 2 diabetes in China, is being investigated for its potential anti-aging effects.
- A 26-week clinical trial involving 150 adults with type 2 diabetes compared henagliflozin to a placebo, alongside consistent diet and exercise recommendations.
Henagliflozin: Slowing Aging?
Henagliflozin, approved for type 2 diabetes in China, is being investigated for its potential anti-aging effects. Clinical trials suggest it may impact biomarkers associated with aging, sparking debate about repurposing existing drugs for longevity.
Study Details
A 26-week clinical trial involving 150 adults with type 2 diabetes compared henagliflozin to a placebo, alongside consistent diet and exercise recommendations.
Key Findings
| biomarker | Henagliflozin Group | Placebo Group |
|---|---|---|
| Telomere Length | Increased (suggesting slower aging) | No significant change |
| PGC-1α Levels | Boosted (supports cell repair & growth) | No significant change |
| Fatty acid Oxidation | Significantly Higher | No significant change |
| Mitochondrial Respiration | Improved | No significant change |
| Senescent Cell Clearance | Increased | No significant change |
Beyond biomarker changes, participants taking henagliflozin demonstrated improved cellular energy use and enhanced immune function, specifically increased clearance of senescent cells.
Henagliflozin vs. SGLT2 Inhibitors
Henagliflozin belongs to the SGLT2 inhibitor class of drugs. Further research is needed to determine if other drugs in this class exhibit similar anti-aging properties.